All medical devices implanted into the human body are perceived as foreign objects, resulting in an attempt by the body to reject them through a process called foreign body reaction. This can result in either the failure of the medical device and/or significant clinical complications. Hylomorph has developed Hylomate, the world's first solution to protect all implantable medical devices in contact with soft tissues from foreign body reaction, acting as an "invisibility" cloak through complex interactions at the microscopic level with the surrounding tissue.
Hylomate is a platform technology that addresses all causes of severe complications connected to the implantation of synthetic materials. It ensures an all-round protection of the surgical pocket, preventing infection, hematoma, foreign body reaction and fibrotic encapsulation. Hylomate increases the lifespan of implants and minimizes exposure to life-threatening risk. This results in (1) improve quality - of - life for patients (2) better quality-of-care for healthcare providers and (3) reduced health economics burden. The first application for Hylomate will be in the field of cardiac rhythm management in combination with pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices.
The completion of ESPREE will put Hylomorph in the position to successfully pursue an additional financing round, to set-up sales and marketing forces in the US and Europe to demonstrate commercial traction of Hylomate during the showcasing phase.
